Admission cardiac and renal biomarkers for early identification of type 1 cardiorenal syndrome after acute myocardial infarction
- 1Laboratory Department, the 964th Hospital of the Joint Logistics Support Force, No. 4799 Xi’an Road, lvyuan District, Changchun, Jilin Province 130000 China
Abstract
This retrospective study evaluated the diagnostic screening and early identification value of admission baseline cardiac and renal biomarkers for newly developed in-hospital type 1 cardiorenal syndrome (CRS) after acute myocardial infarction (AMI). Baseline samples were collected at emergency admission before the documented onset of renal injury. A total of 150 AMI patients were included, comprising 60 patients who developed incident CRS and 90 AMI controls without renal impairment. Laboratory indicators included cardiac markers (cardiac troponin I [cTnI] and N-terminal pro-B-type natriuretic peptide [NT-proBNP]) and renal-related markers including retinol-binding protein (RBP), urea, serum creatinine and spot urinary microalbumin. Multivariate logistic regression adjusted for infarct size, haemodynamic status, baseline renal function, comorbidities and guideline-directed cardiovascular medications, and ROC analysis assessed discriminatory performance. Baseline urea, urinary microalbumin and NT-proBNP were higher, while RBP was lower, in patients who developed CRS (all P < 0.0001). Independently associated indicators included cTnI (OR = 0.628, 95% CI: 0.436–0.903, P = 0.012), RBP (OR = 0.931, 95% CI: 0.883–0.981, P = 0.008), urea (OR = 1.226, 95% CI: 1.039–1.446, P = 0.016) and urinary microalbumin (OR = 1.017, 95% CI: 1.004–1.031, P = 0.013). Urea showed the highest AUC (0.914; sensitivity, 78.5%; specificity, 83.4%). Raw urinary microalbumin showed an AUC of 0.747, and urinary microalbumin showed improved discriminatory performance after urine creatinine calibration and covariate adjustment (AUC = 0.883). Combined assessment of these biomarkers may support diagnostic screening of AMI patients at increased risk of in-hospital CRS.
Related
- Association Between Admission Calculated Serum Osmolality and New-Onset Atrial Fibrillation in Patients with Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
- Community-Level Wastewater Surveillance of Nicotine Biomarkers Tracks Cardiovascular Disease Burden and Myocardial Infarction
- Admission Endothelial Activation and Stress Index in Acute Myocardial Infarction: Incremental Value Beyond the GRACE Score and a Test of the Index Weights
- Association Between Admission Estimated Glomerular Filtration Rate and Long-Term Mortality in Patients with Acute Myocardial Infarction
- Circulating CARMN for acute myocardial infarction prognosis and its incremental effect when combined with conventional biomarkers
BibTeX
@article{guo2026admission,
title = {{Admission cardiac and renal biomarkers for early identification of type 1 cardiorenal syndrome after acute myocardial infarction}},
author = {Ge Guo and Yun Zhao},
journal = {BMC Cardiovascular Disorders},
year = {2026},
month = aug,
doi = {10.1186/s12872-026-06350-2},
url = {https://doi.org/10.1186/s12872-026-06350-2},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Admission cardiac and renal biomarkers for early identification of type 1 cardiorenal syndrome after acute myocardial infarction
AU - Ge Guo
AU - Yun Zhao
PY - 2026
DA - 2026/08/07
JO - BMC Cardiovascular Disorders
DO - 10.1186/s12872-026-06350-2
UR - https://doi.org/10.1186/s12872-026-06350-2
AB - This retrospective study evaluated the diagnostic screening and early identification value of admission baseline cardiac and renal biomarkers for newly developed in-hospital type 1 cardiorenal syndrome (CRS) after acute myocardial infarction (AMI). Baseline samples were collected at emergency admission before the documented onset of renal injury. A total of 150 AMI patients were included, comprising 60 patients who developed incident CRS and 90 AMI controls without renal impairment. Laboratory indicators included cardiac markers (cardiac troponin I [cTnI] and N-terminal pro-B-type natriuretic peptide [NT-proBNP]) and renal-related markers including retinol-binding protein (RBP), urea, serum creatinine and spot urinary microalbumin. Multivariate logistic regression adjusted for infarct size, haemodynamic status, baseline renal function, comorbidities and guideline-directed cardiovascular medications, and ROC analysis assessed discriminatory performance. Baseline urea, urinary microalbumin and NT-proBNP were higher, while RBP was lower, in patients who developed CRS (all P < 0.0001). Independently associated indicators included cTnI (OR = 0.628, 95% CI: 0.436–0.903, P = 0.012), RBP (OR = 0.931, 95% CI: 0.883–0.981, P = 0.008), urea (OR = 1.226, 95% CI: 1.039–1.446, P = 0.016) and urinary microalbumin (OR = 1.017, 95% CI: 1.004–1.031, P = 0.013). Urea showed the highest AUC (0.914; sensitivity, 78.5%; specificity, 83.4%). Raw urinary microalbumin showed an AUC of 0.747, and urinary microalbumin showed improved discriminatory performance after urine creatinine calibration and covariate adjustment (AUC = 0.883). Combined assessment of these biomarkers may support diagnostic screening of AMI patients at increased risk of in-hospital CRS.
SN - 1471-2261
ER -